Evidence map›Paper›PMID 34488453›Full record

ArticlemBio2021

Immunological Profiling of COVID-19 Patients with Pulmonary Sequelae.

Jianghua Wu, Lu Tang, Yanling Ma, Yu Li, Dongmei Zhang, Qian Li, Heng Mei, Yu Hu

Open access · goldAbstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jianghua Wu *Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lu Tang *Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yanling Ma *Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu Li *Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Dongmei ZhangDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0003-3908-9025
Qian LiInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Heng MeiInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu HuInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Union Hospital · CN

Funding

Fundamental Research Funds for the Central universities NO.2020KFYXGYJ029Scientific Research Projects of Academy of Engineering N0.2020-KYGG-01-07The key special project of ministry of science and technology, China NO.2020YFC0845700
6 · The paper itself

Abstract

Cellular immunity may be involved in organ damage and rehabilitation in patients with coronavirus disease 2019 (COVID-19). We aimed to delineate immunological features of COVID-19 patients with pulmonary sequelae (PS) 1 year after discharge. Fifty COVID-19 survivors were recruited and classified according to radiological characteristics, including 24 patients with PS and 26 patients without PS. Phenotypic and functional characteristics of immune cells were evaluated by multiparametric flow cytometry. Patients with PS had an increased proportion of natural killer (NK) cells and a lower percentage of B cells than patients without PS. Phenotypic and functional features of T cells in patients with PS were predominated by the accumulation of CD4-positive (CD4

Indexed as

AdultCD28 AntigensCD4-Positive T-LymphocytesCD57 AntigensCD8-Positive T-LymphocytesCOVID-19FemaleHepatitis A Virus Cellular Receptor 2HumansImmunity, CellularInterleukin-17Interleukin-2Interleukin-4L-SelectinMaleMiddle AgedCD28 AntigensCD57 AntigensHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Interleukin-17Interleukin-2Interleukin-4L-SelectinNatural Cytotoxicity Triggering Receptor 1Natural Cytotoxicity Triggering Receptor 3NCR1 protein, humanNCR3 protein, humancellular immunityCOVID-19pulmonary sequelae

Identifiers

PMID34488453
PMCPMC8546863
OpenAlexW3196316282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.